StockData
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. (FDMT) stock

FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3015% below fair value
$10.79−0.50 (-4.43%)

Close on Nov 17, 2026Market cap $778.82MP/E –Yield –

4D Molecular Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

4D Molecular Therapeutics's price to sales ratio was 7.8× on Nov 11, 2026, against 24.7× a year earlier. Over the last 3 years it ranged from 5.9× to 396.8×, with a median of 31.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20267.8×−25.7
2024Jan 31, 202433.5×−5.9
2023Dec 29, 202339.4×−325.2
2022Dec 30, 2022364.6×+333.2
2021Jan 29, 202131.4×+0.7
2020Dec 31, 202030.7×–

More 4D Molecular Therapeutics figures

See a number that looks wrong?